Trial Profile
An Open-label, Parallel-group, Single Dose Study to Assess the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Renal Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2020
Price :
$35
*
At a glance
- Drugs Pradigastat (Primary)
- Indications Coronary artery disease; Dyslipidaemias; Hepatitis C; Hyperlipoproteinaemia type I; Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novartis
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 13 Jun 2012 Trial location (USA) identified as reported by ClinicalTrials.gov.
- 13 Jun 2012 Actual initiation date May 2012 added as reported by ClinicalTrials.gov.